Conjugated antisense compounds and their use
US11725208B2 · kind B2 · utility
1Cited by
72References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 14, 2018 |
| Grant date | Aug 15, 2023 |
| Priority date | — |
| Expiry date | Feb 14, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y207/11001
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides half duplex compounds comprising a first oligomeric compound and a second, shorter, oligomeric compound, wherein the first oligomeric compound is complementary to a target nucleic acid and the second oligomeric compound is complementary to the first oligomeric compound. In certain embodiments, the compounds disclosed herein are useful for modulating the expression of extra-hepatic target nucleic acids.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.